scholarly journals Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study

2014 ◽  
Vol 95 (6) ◽  
pp. 557-563 ◽  
Author(s):  
Hiroshi Hagino ◽  
Seitaro Yoshida ◽  
Junko Hashimoto ◽  
Masayuki Matsunaga ◽  
Masato Tobinai ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Fracture Risk ◽  
Risk Reduction ◽  
Bone Mineral ◽  
Primary Osteoporosis ◽  
Mineral Density ◽  
Fracture Risk Reduction ◽  
Mover Study

Bone mineral density as a surrogate biomarker for fracture risk reduction – Authors' reply

2020 ◽  
Vol 8 (11) ◽  
pp. 876
Author(s):  
Dennis M Black ◽  
Mary L Bouxsein ◽  
Douglas C Bauer ◽  
Richard Eastell
Keyword(s):  
Bone Mineral Density ◽  
Fracture Risk ◽  
Risk Reduction ◽  
Bone Mineral ◽  
Mineral Density ◽  
Fracture Risk Reduction

Bone mineral density as a surrogate biomarker for fracture risk reduction

2020 ◽  
Vol 8 (11) ◽  
pp. 875-876
Author(s):  
Josivan G Lima ◽  
Lucia H C Nóbrega ◽  
Marcel C F Santos ◽  
Breno C C Simas
Keyword(s):  
Bone Mineral Density ◽  
Fracture Risk ◽  
Risk Reduction ◽  
Bone Mineral ◽  
Mineral Density ◽  
Fracture Risk Reduction

scholarly journals Relationship Between Bone Mineral Density Changes and Fracture Risk Reduction in Patients Treated With Strontium Ranelate

2008 ◽  
Vol 63 (1) ◽  
pp. 36-37
Author(s):  
Olivier Bruyere ◽  
Christian Roux ◽  
Johann Detilleux ◽  
Daniel O. Slosman ◽  
Tim D. Spector ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Fracture Risk ◽  
Risk Reduction ◽  
Bone Mineral ◽  
Strontium Ranelate ◽  
Mineral Density ◽  
Fracture Risk Reduction

scholarly journals 24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk

2017 ◽  
Vol 34 (7) ◽  
pp. 1727-1740 ◽  
Author(s):  
Toshitsugu Sugimoto ◽  
Masataka Shiraki ◽  
Masao Fukunaga ◽  
Hiroshi Hagino ◽  
Teruki Sone ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Fracture Risk ◽  
Bone Mineral ◽  
Primary Osteoporosis ◽  
Mineral Density ◽  
Open Label ◽  
High Fracture ◽  
Efficacy Research

scholarly journals Glucocorticoid-Induced Bone Loss Is Associated with Abnormal Intravertebral Areal Bone Mineral Density Distribution

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Louise I. Manning ◽  
Andrew M. Briggs ◽  
Sharon Van Doornum ◽  
Ashwini Kale ◽  
Susan Kantor ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Vertebral Fracture ◽  
Bone Loss ◽  
Fracture Risk ◽  
Bone Mineral ◽  
Vertebral Body ◽  
Areal Bone Mineral Density ◽  
Primary Osteoporosis ◽  
Mineral Density ◽  
Vertebral Fracture Risk

Individuals with glucocorticoid-induced osteoporosis experience vertebral fractures at an increased rate and at higher vertebral areal bone mineral density (aBMD) than individuals with primary osteoporosis. Standard posteroanterior- (PA-) projection dual energy X-ray absorptiometry (DXA) lacks the diagnostic sensitivity required for reliable estimation of vertebral fracture risk in individuals. Assessment of subregional vertebral aBMD using lateral-projection DXA may improve the predictive value of DXA parameters for fracture. One hundred and four individuals were recruited and grouped for this study: primary osteoporosis with no history of vertebral fracture (n=43), glucocorticoid-induced bone loss (n=13), and healthy controls (n=48). Standard PA-projection and supine-lateral scans were performed, and lateral scans were analysed according to an established protocol to measure aBMD within 6 subregions. Main effects for subregion and group were assessed and observed, by ANCOVA. Ratios were calculated between subregions and compared between groups, to overcome the potentially confounding influence of variability in subregional geometry. Significantly lower values were observed in the glucocorticoid group for the ratios of (i) anterior subregion: whole vertebral body and (ii) posterior: whole vertebral body when compared to the primary osteoporosis and control groups (P<0.05). Lower anterior subregional aBMD in individuals on glucocorticoid therapy may help to explain the increased vertebral fracture risk in this patient group.

Sign in / Sign up

Export Citation Format

Share Document